Opinion

Video

Impact of Transplant Eligibility on Treatment Selection

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.

Video content above is prompted by the following:

  • How does transplant eligibility impact first-line treatment goals and selection of initial therapy?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video
5 experts in this video
3 experts are featured in this series.
Related Content
Bispecific antibodies | Image Credit: © Galina - stock.adobe.com
January 16th 2025

Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

CAR T-cells targeting cancer cells | Image Credit: © furyon - stock.adobe.com
January 2nd 2025

Equecabtagene Autoleucel Shows Efficacy, Safety in Treatment of Patients With Heavily Pretreated Multiple Myeloma

Alexandra Gerlach, Associate Editor
Multiple myeloma cells -- Image credit: Saiful52 | stock.adobe.com
December 26th 2024

Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies

Amir Ali, PharmD, BCOP Kevin Le, PharmD, BCOP Tanjia Toma, PharmD Candidate Soumar Haddad, PharmD Candidate Fleuri Dindar, PharmD Candidate Bryan Ceballos, PharmD Candidate
Multiple myeloma under microscope -- Image credit: Saiful52 | stock.adobe.com
December 23rd 2024

Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials

Mike Hennessy Jr, President and CEO
multiple myeloma
December 9th 2024

Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Alana Hippensteele, Lead Editor